Drug · CHEMBL36
PYRIMETHAMINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PYRIMETHAMINE. Drugs and targets, record CHEMBL36. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL36
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Chloridine, GNF-PF-5586, NSC-3061, Pirimetamina, Pyrimethaminum, RP-4753, TCMDC-123831, TCMDC-125860, WR-2978
- ChEMBL
- Open Targets' highest stage
- Approval, for 3 of its 23 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases23
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| malaria | Approval | ATC, DailyMed and TTD | 24 | 20 | https://conductscience.org/library/drugs?q=MONDO_0005136 |
| Plasmodium falciparum malaria | Phase 3 | ClinicalTrials.gov | 12 | 12 | https://conductscience.org/library/drugs?q=MONDO_0005920 |
| Plasmodium vivax malaria | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0005921 |
| HIV infectious disease | Phase 1/2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005109 |
| Sandhoff disease | Phase 1/2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0010006 |
| Tay-Sachs disease | Phase 1/2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0010100 |
| autoimmune lymphoproliferative syndrome | Phase 1 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0017979 |
| schistosomiasis | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0015254 |
| AIDS | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0012268 |
| B-cell chronic lymphocytic leukemia | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0004948 |
1 to 10 of 23Source Open Targets
See all 23 diseasesTrials181
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 5 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03143218 | Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) | Phase 3 | 5,920 | 2022-01-28 | sulphadoxine/pyrimethamine | A combination that names it | ClinicalTrials.gov |
| NCT04319380 | Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study | Phase 3 | 5,098 | 2024-09-20 | sulphadoxine-pyrimethamine | A combination that names it | ClinicalTrials.gov |
| NCT01103063 | Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa | Phase 3 | 2,891 | 2014-09-05 | pyrimethamine | Its name | ClinicalTrials.gov |
| NCT04336189 | Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda | Phase 3 | 2,757 | 2025-11-06 | sulfadoxine-pyrimethamine | A combination that names it | ClinicalTrials.gov |
| NCT01443130 | Chloroquine for Malaria in Pregnancy | Phase 3 | 900 | 2015-10-29 | sulfadoxine-pyrimethamine | A combination that names it | ClinicalTrials.gov |
| NCT02793622 | Prevention of Malaria in HIV-uninfected Pregnant Women and Infants | Phase 3 | 782 | 2021-04-14 | sulfadoxine-pyrimethamine | A combination that names it | ClinicalTrials.gov |
| NCT00852371 | Intermittent Preventive Treatment of Malaria in Schoolchildren | Phase 3 | 780 | 2024-03-21 | sulfadoxine-pyrimethamine | A combination that names it | ClinicalTrials.gov |
| NCT00948896 | Chemopreventive Therapy for Malaria in Ugandan Children | Phase 3 | 600 | 2015-08-04 | sulfadoxine-pyrimethamine | A combination that names it | ClinicalTrials.gov |
| NCT02163447 | Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants | Phase 3 | 300 | 2018-11-14 | sulfadoxine-pyrimethamine | A combination that names it | ClinicalTrials.gov |
| NCT03952650 | Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa... | Phase 1/2 | 252 | 2022-07-12 | pyrimethamine | Its name | ClinicalTrials.gov |
1 to 10 of 181
See all 181 trialsComparisons in its trials14
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy vs Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy: Prevalence of Anemia in Pregnant Women | 28 of 375 | 8 of 373 | 748 | NCT02793622 | Trial comparisons |
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy vs Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy: Number of Participants With Adverse Events | 54 of 375 | 43 of 373 | 748 | NCT02793622 | Trial comparisons |
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy vs Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy: deaths from any cause | 1 of 375 | 3 of 373 | 748 | NCT02793622 | Trial comparisons |
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy vs Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy: serious adverse events | 11 of 375 | 19 of 373 | 748 | NCT02793622 | Trial comparisons |
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy vs Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy: Prevalence of Maternal Malaria | 28 of 336 | 1 of 342 | 678 | NCT02793622 | Trial comparisons |
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy vs Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy: Incidence of Complicated Malaria in Infants | 44 of 339 | 24 of 339 | 678 | NCT02793622 | Trial comparisons |
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy vs Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy: Infant Mortality Rate | 9 of 339 | 7 of 339 | 678 | NCT02793622 | Trial comparisons |
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy vs Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy: Incidence of Hospital Admissions in Infants | 19 of 339 | 8 of 339 | 678 | NCT02793622 | Trial comparisons |
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy vs Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy: Number of Participants Who Deliver With a Composite Adverse Birth Outcome | 60 of 329 | 54 of 337 | 666 | NCT02793622 | Trial comparisons |
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy vs Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy: Prevalence of Placental Malaria by Histology | 197 of 322 | 94 of 331 | 653 | NCT02793622 | Trial comparisons |
1 to 10 of 14
See all 14 comparisons in its trialsPapers from its trials223
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL36
GET https://conductscience.org/api/drugs/v1/CHEMBL36/diseases?page=2